UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AS03- and MF59-Adjuvanted Influenza Vaccines in Children

Frontiers in immunology, 2017-12, Vol.8, p.1760-1760

2017

Volltextzugriff (PDF)

Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad

Revista española de quimioterapia, 2023-08, Vol.36 (4), p.334-345

2023

Volltextzugriff (PDF)

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

Frontiers in immunology, 2023-09, Vol.14, p.1283355-1283355

2023

Volltextzugriff (PDF)

Smart combination of aluminum hydroxide and MF59 to induce strong cellular immune responses

Journal of controlled release, 2022-09, Vol.349, p.699-711

2022

Volltextzugriff (PDF)

Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience

International journal of infectious diseases, 2019-08, Vol.85, p.S1-S9

2019

Volltextzugriff (PDF)

Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood

Proceedings of the National Academy of Sciences - PNAS, 2016-02, Vol.113 (7), p.1853-1858

2016

Volltextzugriff (PDF)

Adjuvanted influenza vaccines

Human vaccines & immunotherapeutics, 2018-03, Vol.14 (3), p.550-564

2018

Volltextzugriff (PDF)

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

Frontiers in immunology, 2022-09, Vol.13, p.1002286-1002286

2022

Volltextzugriff (PDF)

The mechanism of action of MF59 – An innately attractive adjuvant formulation

Vaccine, 2012-06, Vol.30 (29), p.4341-4348

2012

Volltextzugriff (PDF)

Systems analysis of human vaccine adjuvants

Seminars in immunology, 2018-10, Vol.39 (C (Special Issue: SI )), p.30-34

Harandi, Ali M.

2018

Volltextzugriff (PDF)

Immunology and efficacy of MF59-adjuvanted vaccines

Human vaccines & immunotherapeutics, 2018-12, Vol.14 (12), p.3041-3045

2018

Volltextzugriff (PDF)

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis

Influenza and other respiratory viruses, 2021-11, Vol.15 (6), p.813-823

2021

Volltextzugriff (PDF)

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older

International journal of infectious diseases, 2019-08, Vol.85, p.S10-S17

2019

Volltextzugriff (PDF)

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children

International journal of infectious diseases, 2019-08, Vol.85, p.S26-S38

2019

Volltextzugriff (PDF)

MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications

International journal of infectious diseases, 2019-08, Vol.85, p.S18-S25

2019

Volltextzugriff (PDF)

Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine

Vaccine, 2023-11, Vol.41 (49), p.7409-7418

2023

Volltextzugriff (PDF)

Comparison of the safety and immunogenicity of an MF59® -adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects

Vaccine, 2014-09, Vol.32 (39), p.5027-5034

2014

Volltextzugriff (PDF)

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

Vaccine, 2018-10, Vol.36 (41), p.6202-6211

2018

Volltextzugriff (PDF)

The history of MF59® adjuvant: a phoenix that arose from the ashes

Expert review of vaccines, 2013-01, Vol.12 (1), p.13-30

2013

Volltextzugriff (PDF)

Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age

Reviews in medical virology, 2023-05, Vol.33 (3), p.e2329-n/a

2023

Volltextzugriff (PDF)

Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway

eLife, 2020-06, Vol.9

2020

Volltextzugriff (PDF)

Molecular and cellular signatures of human vaccine adjuvants

Proceedings of the National Academy of Sciences - PNAS, 2008-07, Vol.105 (30), p.10501-10506

2008

Volltextzugriff (PDF)

Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity

Biomaterials, 2020-12, Vol.262, p.120342-120342, Article 120342

2020

Volltextzugriff (PDF)

Physical radiofrequency adjuvant enhances immune responses to influenza H5N1 vaccination

The FASEB journal, 2022-03, Vol.36 (3), p.e22182-n/a

2022

Volltextzugriff (PDF)

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant

Viruses, 2022-02, Vol.14 (3), p.501

2022

Volltextzugriff (PDF)

1 – 25 von 180

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(149)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(159)
Life Sciences & Biomedicine
(153)
Mf59
(138)
Humans
(112)
Immunology
(109)
Vaccines
(88)
Influenza
(80)
Adjuvants, Immunologic - Administration & Dosage
(78)
Female
(72)
Influenza, Human - Prevention & Control
(68)
Polysorbates - Administration & Dosage
(68)
Squalene - Administration & Dosage
(68)
Influenza Vaccines - Immunology
(67)
Medicine, Research & Experimental
(64)
Research & Experimental Medicine
(64)
Influenza Vaccines - Administration & Dosage
(61)
Male
(59)
Adjuvant
(53)
Adjuvants
(50)
Animals
(49)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AS03- and MF59-Adjuvanted Influenza Vaccines in Children

Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en población de 65 o más años de edad

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

Smart combination of aluminum hydroxide and MF59 to induce strong cellular immune responses

Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience

Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood

Adjuvanted influenza vaccines

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

The mechanism of action of MF59 – An innately attractive adjuvant formulation

Systems analysis of human vaccine adjuvants

Immunology and efficacy of MF59-adjuvanted vaccines

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children

MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications

Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine

Comparison of the safety and immunogenicity of an MF59® -adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

The history of MF59® adjuvant: a phoenix that arose from the ashes

Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age

Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway

Molecular and cellular signatures of human vaccine adjuvants

Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity

Physical radiofrequency adjuvant enhances immune responses to influenza H5N1 vaccination

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant

Suchergebnisse filtern